title: Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
abstract: BReast CAncer genes 1 and 2 (BRCA1 and BRCA2) mutation carriers diagnosed with breast cancer are at increased risk of developing a second primary breast cancer. Data from high-risk clinics may be subject to different biases which can cause both over and underestimation of this risk. Using data from a large multi-institutional family registry we estimated the 10-year cumulative risk of second primary breast cancer including more complete testing information on family members. We prospectively followed 800 women diagnosed with breast cancer from the Breast Cancer Family Registry (BCFR) who were carriers of a BRCA1 or BRCA2 pathogenic mutation or a variant of unknown clinical significance. In order to limit survival and ascertainment bias, cases were limited to those diagnosed with a first primary breast cancer from 1994 to 2001 and enrolled in the BCFR within 3 years after their cancer diagnosis. We excluded women enrolled after being diagnosed with a second breast cancer. We calculated 10-year incidence of second primary breast cancers. The 10-year incidence of a second primary breast cancer was highest in BRCA1 mutation carriers (17 %; 95 % CI 11-25 %), with even higher estimates in those first diagnosed under the age of 40 (21 %; 95 % CI 13-34 %). Lower rates were found in BRCA2 mutation carriers (7 %; 95 % CI 3-15 %) and women with a variant of unknown clinical significance (6 %; 95 % CI 4-9 %). Whereas the cumulative 10-year incidence of second primary breast cancer is high in BRCA1 mutation carriers, the estimates in BRCA2 mutation carriers and women with variants of unknown clinical significance are similar to those reported in women with sporadic breast cancer.
authors.affiliation: Department of Surgery, Tel Aviv Sourasky Medical Center, 6 Weizman St, Tel Aviv, Israel, tehillahm@tlvmc.gov.il.
authors.forename: Tehillah S
authors.initials: TS
authors.lastname: Menes
authors.forename: Mary Beth
authors.initials: MB
authors.lastname: Terry
authors.forename: David
authors.initials: D
authors.lastname: Goldgar
authors.forename: Irene L
authors.initials: IL
authors.lastname: Andrulis
authors.forename: Julia A
authors.initials: JA
authors.lastname: Knight
authors.forename: Esther M
authors.initials: EM
authors.lastname: John
authors.forename: Yuyan
authors.initials: Y
authors.lastname: Liao
authors.forename: Melissa
authors.initials: M
authors.lastname: Southey
authors.forename: Alexander
authors.initials: A
authors.lastname: Miron
authors.forename: Wendy
authors.initials: W
authors.lastname: Chung
authors.forename: Saundra S
authors.initials: SS
authors.lastname: Buys
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006579:Heterozygote; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D055815:Young Adult